Archive
SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease
BETHESDA, Md., March 7, 2012 (CRWENewswire) -- Spherix Incorporated (NASDAQ: SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of ... [Read more]
Discovery Labs Announces FDA Approval of SURFAXIN® (lucinactant) for Prevention of Respiratory Distress Syndrome
SURFAXIN is the First FDA-Approved Synthetic, Peptide-Containing Surfactant Conference Call Tomorrow at 10 a.m. EST WARRINGTON, Pa., March 6, 2012 (CRWENewswire) -- Discovery Laboratories, Inc. (NAS... [Read more]
PAREXEL Reports Second Quarter Fiscal Year 2012 Financial Results
- Consolidated service revenue of $333.2 million grew 9.5% year-over-year - GAAP operating margin of 6.8%; adjusted operating margin of 7.1% excluding net restructuring charges of $1.2 mi... [Read more]
Spherix Announces Successful Completion of Important Toxicology Study of SPX-106
Readies IND Filing BETHESDA, MD, Jan 11, 2012 (CRWENEWSWIRE) -- Spherix Incorporated (NASDAQ:SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and athero... [Read more]
Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
Results to Be Presented Wednesday, October 26, at AAPS National Meeting in Washington, DC BETHESDA, MD, Oct. 24, 2011 (CRWENEWSWIRE) -- Spherix Incorporated (NASDAQ:SPEX) -- an innovator in... [Read more]
